Skip to main content

Advertisement

SpringerLink
Log in

Monoclonal Antibody-Directed Cytotoxic Therapy

Potential in Malignant Diseases of Aging

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The advent of monoclonal antibodies has allowed the development of tumour directed therapies utilising antibody-dependent effector mechanisms and immunoconjugates (e.g. drug, isotope and toxin coupled antibodies) against human malignancies. Preclinical studies in mouse tumour models have been most impressive and have led to numerous clinical trials. Whereas the majority of these phase I/II trials have been less impressive, a few trials have shown efficacy in highly pre-treated refractory patients and have led to phase III trials. The therapeutic monoclonal antibodies examined in these trials will become clinically available in the near future.

In this review, various methods of utilising antibody-directed anticancer strategies are presented, with emphasis on recent advances in the field. The advantages and disadvantages of these methods together with the role of antibody-directed therapeutics in cancer management are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoel DG, Davis DL, Miller AB, et al. Trends in cancer mortality in 15 industrialised countries 1969–1986. J Natl Cancer Inst 1992; 84: 313–20

    Article  PubMed  CAS  Google Scholar 

  2. Ries LAG, Kosary CL, Hanky BF, et al. (editors). SEER cancer statistic review, 1973–1995. Bethesda (MD): National Cancer Institute, 1998

    Google Scholar 

  3. Double JA, Bibby MC. Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst 1989; 81: 988–99

    Article  PubMed  CAS  Google Scholar 

  4. Erlich P. Collected studies on immunity. Vol. II. New York: John Wiley, 1906

    Google Scholar 

  5. Pietersz GA, McKenzie IFC. Antibody conjugates for the treatment of cancer. Immunol Rev 1992; 129: 57–80

    Article  PubMed  CAS  Google Scholar 

  6. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev 1984; 36: 277–336

    PubMed  CAS  Google Scholar 

  7. Mathe G, Loc TB, Bernard JC. Effect sur la leucemie 1210 del la souris d’un combinaison par diazotation d’amethopterine et de gamma globulines de hamsters porteursde cette leucemie par hetirogreffe. C R Seances Acad Sci D 1958; 246: 1626–8

    CAS  Google Scholar 

  8. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7

    Article  PubMed  CAS  Google Scholar 

  9. Schroff RW, Woodhouse CS, Foon KA, et al. Intratumour localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000 dalton melanoma associated antigen. J Natl Cancer Inst 1985; 74: 299–306

    PubMed  CAS  Google Scholar 

  10. Herlyn DM, Steplewski Z, Herlyn MF, et al. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40: 717–21

    PubMed  CAS  Google Scholar 

  11. Katano M, Irie RF. Human monoclonal antibody to tumour associated ganglioside GD2: suppressed growth of human melanoma in nude mice. Immunol Lett 1984; 8: 169–74

    Article  PubMed  CAS  Google Scholar 

  12. Dillman RO, Shawler DL, Sobol RE, et al. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukaemia. Blood 1989; 59: 1036–45

    Google Scholar 

  13. Miller RA, Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 1981; II: 226–30

    Article  Google Scholar 

  14. Ritz J, Pesando JM, Sallan SE, et al. Serotherapy of acute lymphoblastic leukaemia with monoclonal antibody. Blood 1981; 58: 141–52

    PubMed  CAS  Google Scholar 

  15. Adams DO, Hall T, Steplewski Z, et al. Tumours undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci 1984; 81: 3506–10

    Article  PubMed  CAS  Google Scholar 

  16. Goodman GE, Beaumier P, Hellstrom I, et al. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3: 340–52

    PubMed  CAS  Google Scholar 

  17. Sears HG, Atkinson B, Mattis J, et al. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; I: 762–5

    Article  Google Scholar 

  18. Adair AT. Engineered antibodies for therapy. Immunol Rev 1992; 130: 5–40

    Article  PubMed  CAS  Google Scholar 

  19. Meredith RF, Khazaeli MB, Plott WE, et al. Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer. Antibody Immunoconjugates Radiopharm 1992; 5 (1): 75–80

    Google Scholar 

  20. LoBuglio A, Wheeler R, Trang J, et al. Human/mouse chimeric monoclonal antibodies in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989; 86: 4220–4

    Article  PubMed  CAS  Google Scholar 

  21. Michaelson TE, Aase A, Norderdaug L, et al. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse/human IgG subclasses and IgG3 antibodies with altered hinge regions. Mol Immunol 1992; 29: 319–26

    Article  Google Scholar 

  22. Guadagni F, Schlom J, Pothen S, et al. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 1988; 26: 222–30

    Article  PubMed  CAS  Google Scholar 

  23. Vuist WMJ, Buitenen FV, Hekman A, et al. Two distinct mechanisms of antitumour activity mediated by the combination of interleukin 2 and monoclonal antibodies. Cancer Res 1990; 50: 5767–72

    PubMed  CAS  Google Scholar 

  24. Nakamura K, Kubo A. Biodistribution of iodine-125 labeled monoclonal antibody/interleukin 2 immunoconjugate in athymic mice bearing human tumour xenografts. Cancer 1997; 80 (12): 2650–5

    Article  PubMed  CAS  Google Scholar 

  25. Borrione P, Montacchini L, Beggiato E, et al. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin 2. Leuk Lymphoma 1996; 21: 325–30

    Article  PubMed  CAS  Google Scholar 

  26. Bock SN, Cameron RB, Kragel P, et al. Biological and antitumour effects of recombinant human macrophage colony stimulating factor in mice. Cancer Res 1991; 51: 2649–54

    PubMed  CAS  Google Scholar 

  27. Stevenson GT, Glennie MJ. Surface immunoglobulin of B-lymphocytic tumours as a therapeutic target. Cancer Surv 1980; 4: 213–44

    Google Scholar 

  28. Eisenthal A, Rosenberg SA. Systemic induction of cells mediating antibody dependent cellular cytotoxicity following administration of interleukin-2. Cancer Res 1989; 49: 6953–9

    PubMed  CAS  Google Scholar 

  29. Shiloni E, Eisenthal A, Sachs D, et al. Antibody dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol 1987; 138: 1992–8

    PubMed  CAS  Google Scholar 

  30. Gill I, Agah R, Hu E, et al. Synergistic antitumour effects of interleukin-2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo. Cancer Res 1989; 49: 5377–9

    PubMed  CAS  Google Scholar 

  31. Bajorin DF, Chapman PB, Wong G, et al. Phase I evaluation of a combination of a monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50 (23) 7490–5

    PubMed  CAS  Google Scholar 

  32. Sondel PM, Hank JA. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Cancer J Sci Am 1997; 3 (1 Suppl.): S121

    PubMed  Google Scholar 

  33. Holz E, Raab R, Riethmuller G. Antibody-based immunotherapeutic strategies in colorectal cancer. Recent Results Cancer Res 1996; 142: 381–400

    Article  PubMed  CAS  Google Scholar 

  34. Surfus JE, Hank JA, Oosterwijk E, et al. Anti-renal cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996; 19: 184–91

    Article  PubMed  CAS  Google Scholar 

  35. Data on file, IDEC Pharmaceuticals Corporation and Genentech Inc., 1996

  36. Kelley MJ, Linnoila RI, Avis IL, et al. Antitumour activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997; 112: 256–61

    Article  PubMed  CAS  Google Scholar 

  37. Modjtahedi H, Hickish T, Nicolson M, et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 228–35

    Article  PubMed  CAS  Google Scholar 

  38. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumour Immunol 1996; 19: 419–27

    Article  CAS  Google Scholar 

  39. Buchsbaum DJ, Lawrence TS. New trends in the use of radioimmunoconjugates for the therapy of cancer. Targeted Diagn Ther 1990; 3: 215–55

    PubMed  CAS  Google Scholar 

  40. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336–40

    Article  PubMed  CAS  Google Scholar 

  41. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–24

    Article  PubMed  CAS  Google Scholar 

  42. Denardo GL, Lamborn KR, Goldstein DS, et al. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Cancer 1997; 80 (12 Suppl.): 2706–11

    Article  PubMed  CAS  Google Scholar 

  43. Denardo SJ, Kramer EL, O’Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90Bre-3: results of a phase I clinical trial. J Nucl Med 1997; 38: 1180–5

    PubMed  CAS  Google Scholar 

  44. Kanellos J, Pietersz GA, Cunningham Z, et al. Antitumour activity of aminopterin-monoclonal antibody conjugates: in vitro and in vivo comparison with methotrexate monoclonal antibody conjugates. Immunol Cell Biol 1987; 65: 483–93

    Article  PubMed  CAS  Google Scholar 

  45. Goerlach A, Krauer KG, McKenzie IFC, et al. In vitro antitumour activity of 2’-deoxy-5-fluorouridine monoclonal antibody conjugates. Bioconjug Chem 1991; 2: 96–101

    Article  PubMed  CAS  Google Scholar 

  46. Pietersz GA. The linkage of cytotoxic drugs to monoclonal antibodies for the treatment of cancer. Bioconjug Chem 1990; 1: 89–95

    Article  PubMed  CAS  Google Scholar 

  47. Smyth MJ, Pietersz GA, Classon MJ, et al. The specific targeting of chlorambucil to tumours. J Natl Cancer Inst 1986; 76: 503–10

    PubMed  CAS  Google Scholar 

  48. Peterson BH, DeHerdt SV, Scheck DW, et al. The human immune response to KS1/4-desacetylvinblastine (Ly256787) and KS1/4-deacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res 1991; 51: 2286–90

    Google Scholar 

  49. Blakey DC, Thorpe PE. An overview of therapy with immunotoxins containing ricin or its A-chain. Antibody Immunoconjugates Radiopharm 1988; 1: 1–16

    CAS  Google Scholar 

  50. Lambert JM, Goldmacher VS, Collinson AR, et al. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 1991; 51: 6236–42

    PubMed  CAS  Google Scholar 

  51. Pietersz GA, Kanellos J, McKenzie IFC. Novel synthesis and in vitro characterization of a disulphide linked ricin-monoclonal antibody devoid of galactose binding activity. Cancer Res 1988; 48: 4469–76

    PubMed  CAS  Google Scholar 

  52. Camera L, Del-Vecchio S, Perrillo A, et al. Evaluation of therapeutic response using iodine-131-B72.3 monoclonal antibody in patients with ovarian carcinoma. Eur J Nucl Med 1991; 18: 269–73

    Article  PubMed  CAS  Google Scholar 

  53. Steward JSW, Hird V, Snook D, et al. Intraperitoneal Yttrium-90-labelled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941–51

    Google Scholar 

  54. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177-Lu-CC49: a phase I/II study. Gynecol Oncol 1997; 65: 94–101

    Article  PubMed  CAS  Google Scholar 

  55. Goldenberg DM, Horowtz JA, Sharkey RM, et al. Targeting dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labelled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548–64

    PubMed  CAS  Google Scholar 

  56. Vriesendorp HM, Herpst JM, Germack MA, et al. Phase I-II studies of yttrium labelled antiferritin for end-stage Hodgkin’s disease, including radiation therapy oncology group. J Clin Oncol 1991; 9: 918–28

    PubMed  CAS  Google Scholar 

  57. Ychou M, Pelegrin A, Faurous P, et al. Phase-I/II radio-immunotherapy study with iodine-131 labeled anti-CEA monoclonal antibody F6 F(ab’)2 in patients with nonresectable liver metastases from colorectal cancer. Int J Cancer 1998; 75: 615–9

    Article  PubMed  CAS  Google Scholar 

  58. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumours using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab’)2. J Nucl Med 1996; 37: 1504–10

    PubMed  CAS  Google Scholar 

  59. Cox JP, Jankowski KJ, Kataky R, et al. Synthesis of akinetically stable yttrium-90 labelled macrocycle-antibody conjugate. J Chem Soc Chem Commun 1989: 797–8

    Google Scholar 

  60. Moi MK, Denardo SJ, Meares CF. Stable bifunctional chelates of metals used in radioimmunotherapy. Cancer Res 1990; 50 Suppl.: 789S–793

    PubMed  CAS  Google Scholar 

  61. Harrison A, Walker CA, Parker D, et al. The in vivo release of yttrium-90 from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 1991; 18: 469–76

    CAS  Google Scholar 

  62. Denardo GL, Kroger LA, Denardo SJ, et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994; 73 Suppl.: 1012–22

    Article  PubMed  CAS  Google Scholar 

  63. King DJ, Antoniw P, Owens RJ, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 1995; 72: 1364–72

    Article  PubMed  CAS  Google Scholar 

  64. Juweid M, Swayne LC, Sharkey RM, et al. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anticarcinoembryonic antigen monoclonal antibodies. Gynecol Oncol 1997; 67: 259–71

    Article  PubMed  CAS  Google Scholar 

  65. Ford CHJ, Newman CE, Johnson JR, et al. Localisation and toxicity study of a vindesine-antiCEA conjugate in patients with advanced cancer. Br J Cancer 1983; 47: 35–42

    Article  PubMed  CAS  Google Scholar 

  66. Melino G, Hobbs JR, Radford M, et al. Drug targeting for 7 neuroblastoma patients using human polyclonal antibodies. Protides Biol Fluids 1984; 32: 413–6

    Google Scholar 

  67. Takahashi T, Yamaguchi T, Kitamura K, et al. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988; 61: 881–8

    Article  PubMed  CAS  Google Scholar 

  68. Oldham RK, Lewis M, Orr DW, et al. Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies. Mol Biother 1988; 1: 103–13

    PubMed  CAS  Google Scholar 

  69. Tjandra JJ, Pietersz GA, Smyth MJ, et al. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma-a preliminary report. Surgery 1989; 106: 533–45

    PubMed  CAS  Google Scholar 

  70. Orr D, Oldham R, Lewis M, et al. Phase I trial of mitomycin C immunoconjugate cocktails in human malignancies. Mol Biother 1989; 1: 229–40

    PubMed  CAS  Google Scholar 

  71. Schneck D, Butler F, Dugan W, et al. Phase I studies with a murine monoclonal antibody vinca conjugate (KS1.4-DAVLB) in patients with adenocarcinomas. Antib Immunoconjugates Radiopharm 1989; 2: 93–100

    Google Scholar 

  72. Oldham RK, Lewis M, Orr DW, et al. Individually specified drug immunoconjugates in cancer treatment. Int J Biol Markers 1989; 4: 65–77

    PubMed  CAS  Google Scholar 

  73. Elias DJ, Hirshowitz L, Kline LE, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunoconjugate in patients with non-small cell lung carcinomas. Cancer Res 1990; 50: 4154–9

    PubMed  CAS  Google Scholar 

  74. Data on file, Celltech plc (UK) and Wyeth-Ayerst research of Randor(USA), 1997

  75. Zein N, Sinha AM, McGahren, et al. Calicheamicin γl: an antitumour antibiotic that cleaves double-stranded DNA site specifically. Science 1998; 240: 1198–201

    Article  Google Scholar 

  76. Pimm MV. Drug monoclonal antibody conjugates for cancer therapy: potentials and limitations. CRC Crit Rev Therap Drug Carrier Syst 1988; 5: 189–227

    CAS  Google Scholar 

  77. Byers VS, Rodvien R, Grant K, et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin Xoma Zyme-791 in patients with metastatic colon cancer. Cancer Res 1989; 49: 6153–60

    PubMed  CAS  Google Scholar 

  78. Weiner LM, O’Dwyer J, Kitson J, et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260-F9-recombinant A chain immunoconjugate. Cancer Res 1989; 49: 4062–7

    PubMed  CAS  Google Scholar 

  79. Gould BJ, Borowitz MJ, Groves ES, et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989; 81: 775–81

    Article  PubMed  CAS  Google Scholar 

  80. Oratz R, Speyer JL, Wernz JC, et al. Anti melanoma monoclonal antibody-ricin Achain immunoconjugate (XMME-001-RTA) plus cyclophosphamide in the treatment of malignant melanoma: results of a phase II trial. J Biol Response Mod 1990; 9: 345–54

    PubMed  CAS  Google Scholar 

  81. LeMaistre CF, Rosen S, Frankel A, et al. Phase I trial of H65-RTA immunoconjugate in patients with T-cell lymphoma. Blood 1991; 78: 1173–82

    PubMed  CAS  Google Scholar 

  82. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052–8

    PubMed  CAS  Google Scholar 

  83. Gonzalez R, Salem P, Bunn Jr PA, et al. Single dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol Biother 1991; 3: 192–6

    PubMed  CAS  Google Scholar 

  84. Engert A, Diehl V, Schnell R, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin’s lymphoma. Blood 1997; 89: 403–10

    PubMed  CAS  Google Scholar 

  85. Pai LH, Wittes R, Setser A, et al. Treatment of advanced solid tumours with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996; 2: 350–3

    Article  PubMed  CAS  Google Scholar 

  86. Laske DW, Muraszko KM, Oldfield EH, et al. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 1997; 41: 1039–49

    Article  PubMed  CAS  Google Scholar 

  87. Stone MJ, Sausville EA, Fay JW, et al. Aphase I study of bolus versus continuous infusion of the anti-CD 19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188–97

    PubMed  CAS  Google Scholar 

  88. LoRusso PM, Lomen PL, Redman BG, et al. Phase I study of monoclonal antibody-ricin A chain immunconjugate Xomazyme-791 in patients with metastatic colon cancer. Am J Clin Oncol 1995; 18: 307–12

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Austin Research Institute, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia

    Con Panousis &  Geoffrey A. Pietersz

Authors
  1. Con Panousis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey A. Pietersz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geoffrey A. Pietersz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Panousis, C., Pietersz, G.A. Monoclonal Antibody-Directed Cytotoxic Therapy. Drugs & Aging 15, 1–13 (1999). https://doi.org/10.2165/00002512-199915010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915010-00001

Search

Navigation